June 9, 2020 / 4:14 PM / a month ago

BRIEF-OSE Immunotherapeutics Identifies Monoclonal Antibody Antagonists Of CLEC-1

June 9 (Reuters) - Ose Immunotherapeutics SA:

* IDENTIFIES MONOCLONAL ANTIBODY ANTAGONISTS OF CLEC-1 AS NEW CHECKPOINT INHIBITORS OF IMMUNE MYELOID CELLS IN IMMUNO-ONCOLOGY

* ANTIBODY ANTAGONISTS TARGETING THIS NEW IMMUNE CHECKPOINT REPRESENT A NOVEL APPROACH IN CANCER IMMUNOTHERAPY

* NEW MYELOID IMMUNE CHECKPOINT PATHWAY IDENTIFIED AND CHARACTERIZED

* PRECLINICAL PROGRESS REPORTED WITH CLEC-1 MONOCLONAL ANTIBODY ANTAGONISTS BLOCKING “DON’T EAT ME” SIGNAL Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below